EU To Ask the US to Export AstraZeneca/Oxford Vaccine: Report

  • March 07, 2021 08:58 PM AEDT
  • Suhita Poddar
    Suhita Poddar
    Author Suhita Poddar
    140 Posts

    Suhita is a financial journalist at Kalkine Media. She writes on various topics with a specific interest in the renewable energy sector, sustainability and climate finance. She is a former research analyst with over 9 years of experience in the finan...

EU To Ask the US to Export AstraZeneca/Oxford Vaccine: Report

Source:Mongkolchon Akesin, Shutterstock

Summary

  • The EU will ask the US to export the millions of doses produced domestically to meet its demand.
  • EU countries started their inoculation programme in December but is lagging behind the UK and US due to a shortage of jabs.

Unable to address the supply shortage of AstraZeneca’s Covid-19 vaccines, the European Union has turned to the United States to export the millions of doses produced domestically. According to a report in the Financial Times, the 27-nation EU has sought Washington’s help to ensure a free flow of key ingredients needed for production in Europe.

The vaccine is produced at AstraZeneca’s plants in the UK and EU. It also has production chains in many countries, like the US. As per reports, the US wants to produce the vaccines on its own so that it can run its vaccination programme smoothly.

According to the reports, the EU will now approach the Joe Biden administration to lift the export ban and see that there is a free flow of ingredients needed to produce the jabs.

                                                            

                                                   Copyright © 2021 Kalkine Media Pty Ltd.               

Vaccination drive

The EU has reported that it is lagging behind the Covid-19 vaccination drive as compared to the UK and the US. The EU has approved vaccines of Pfizer/BioNTech, Moderna, and Oxford/AstraZeneca for the vaccination rollout.

Besides, Hungary has also approved doses produced by Chinese firm Sinovac and others.  As per the data provided by the European Centre on Disease Control and Prevention, the EU members have received 43.4 million doses of vaccines, but only 30.6 million doses have been administered till date.

On the other hand, Britain, which was the first European country to approve Pfizer vaccines for mass usage, has already vaccinated more than 21 million people. In contrast, just 8.4 per cent of citizens have got the jabs in the EU members states.

AstraZeneca production troubles

The EU had authorised the AstraZeneca vaccine in January, where the company had first committed to provide 300 million doses by the end of June. But later, it revised the count and said that it could provide about 130 million doses due to production issues at its European plants. Previously, it could not deliver 30 million doses in the last quarter of 2020 due to production pressures from other major countries.

In February, an EU official said that the company has revised its target and now plans to deliver about 40 million doses in Q1, 90 million shots as promised before.

In the same month, the British-Swedish company had reported that it can deliver half of the expected supply of Covid-19 vaccine to the EU and is trying to increase its capacity in its EU chain.

The bloc is facing delays in getting vaccines developed by Pfizer and BioNTech and, Moderna’s shot.

Hurdles for AstraZeneca jabs

The vaccine produced jointly by the Pharmaceutical giant AstraZeneca and Oxford University was temporarily excluded by the South African government after it was found that it was less effective on the new SA virus variants. Besides, the Germany vaccine commission had recommended the jabs for people between 18 and 64 years. Later, WHO experts came to the rescue and said it is fit for people aged over 65.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK